Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial - Bellmunt, J; Hussain, M; Gschwend, JE (Lancet Oncol, 2021)
et al.